Outcomes of Alzheimer's disease therapy with acetylcholinesterase inhibitors and memantine

Expert Opinion on Drug Safety

Volumn 13, Issue 6, 2014, Pages 759-774

  Zemek, Filip ^a   Drtinova, Lucie ^b   Nepovimova, Eugenie ^a,c   Sepsova, Vendula ^a   Korabecny, Jan ^a,c   Klimes, Jiri ^d,e   Kuca, Kamil ^c  

^a UNIVERSITY OF DEFENCE   (Czech Republic)

^b UNIVERSITY OF DEFENCE   (Czech Republic)

^c UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

^d CHARLES UNIVERSITY   (Czech Republic)

^e Institute of Health Economics and Technology Assessment   (Czech Republic)

Author keywords

Acetylcholinesterase; Alzheimer's diseases; Donepezil; Galantamine; Memantine; Rivastigmine

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; MEMANTINE; RIVASTIGMINE; AMINO ACID RECEPTOR BLOCKING AGENT;

ALZHEIMER DISEASE; ANOREXIA; BRADYCARDIA; COGNITION; CONSTIPATION; DIARRHEA; DIZZINESS; DRUG ELIMINATION; DRUG METABOLISM; FAINTNESS; GASTROINTESTINAL HEMORRHAGE; HEADACHE; HUMAN; MAXIMUM PLASMA CONCENTRATION; MEMORY DISORDER; NAUSEA; NAUSEA AND VOMITING; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SLEEP DISORDER; STOMACH ACID SECRETION; STOMACH ULCER; TREATMENT OUTCOME; VOMITING; WEIGHT REDUCTION; ANIMAL; CLINICAL TRIAL (TOPIC); DISEASE COURSE; DRUG DESIGN; PATHOPHYSIOLOGY;

ALZHEIMER DISEASE; ANIMALS; CHOLINESTERASE INHIBITORS; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; DRUG DESIGN; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; MEMANTINE; TREATMENT OUTCOME;

EID: 84901357991     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2014.914168     Document Type: Review

References (105)

1. European Commission Health and Consumers Directorate-General-Directorate C-Public Health and Risk Assessment: Estimated number of people with dementia. Available from: Http://ec.europa.eu/health/ph-information/dissemination/echi/ docs/dementia2-en.pdf(2006) [Accessed January 2012
2. Wimo A, Jonsson L, Gustavsson A, et al. The economic impact of dementia in Europe in 2008-cost estimates from the Eurocode project. Int J Geriatr Psychiatry 2011;26(8):825-32
3. Matthews F, Brayne C. The incidence of dementia in England and Wales: Findings from the five identical sites of the MRC CFA Study. PLoS Med 2005;2:e193
4. Miller EA, Schneider LS, Zbrozek A, Rosenheck RA. Sociodemographic and clinical correlates of utility scores in Alzheimer's disease. Value Health 2008;11:1120-30
5. Wlodarczyk JH, Brodaty H, Hawthorne G, et al. The relationship between quality of life, Mini-Mental State Examination, and the Instrumental Activities of Daily Living in patients with Alzheimer's disease. Arch Gerontol Geriatr 2004;39:25-33
6. Andersen CK, Wittrup-Jensen KU, Lolk A, et al. Ability to perform activities of daily living is the main factor affecting quality of life in patients with dementia. Health Qual Life Outcomes 2004;2:52
7. Karlawish JH, Zbrozek A, Kinosian B, et al. Caregivers' assessments of preference-based quality of life in Alzheimer's disease. Alzheimers Dement 2008;4:203-11 (Pubitemid 351682260
8. Winblad B, Jones RW, Wirth Y, et al. Memantine in moderate to severe Alzheimer's disease: A metaanalysis of randomised clinical trials. Dement Geriatr Cogn Disord 2007;24(1):20-7 (Pubitemid 46985287
9. Heinen-Kammerer T, Rulhoff H, Nelles S, et al. Added therapeutic value of memantine in the treatment of moderate to severe Alzheimer's disease. Clin Drug Investig 2006;26(6):303-14 (Pubitemid 43876564
10. Schneider LS, Dagerman KS, Higgins JP, McShane R. Lack of evidence for the efficacy of memantine in mild Alzheimer disease. Arch Neurol 2011;68(8):991-8
11. Wilkinson D. A review of the effects of memantine on clinical progression in Alzheimer's disease. Int J Geriatr Psychiatry 2012;27(8):769-76
12. Tariot PN, Farlow MR, Grossberg GT, et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: A randomized controlled trial. JAMA 2004;291(3):317-24 (Pubitemid 38101604
13. Porsteinsson AP, Grossberg GT, Mintzer J, Olin JT; Memantine MEM-MD-12 Study Group. Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: A randomized, double-blind, placebocontrolled trial. Curr Alzheimer Res 2008;5(1):83-9
14. Ibach B, Haen E. Acetylcholinesterase inhibition in Alzheimer's disease. Curr Pharm Des 2004;10:231-51
15. Racchi M, Mazzucchelli M, Porrello E, et al. Acetylcholinesterase inhibitors: Novel activities of old molecules. Pharmacol Res 2004;50:441-51 (Pubitemid 39089089
16. Jelic V, Darreh-Shori T. Donepezil: A review of pharmacological characteristics and role in the management of Alzheimer disease. Clin Med Insights: Ther 2010;2:771-88
17. Seltzer B. Donepezil: A review. Expert Opin Drug Metab Toxicol 2005;1:527-36
18. Rodríguez JJ, Noristani HN, Verkhratsky A. The serotonergic systém in ageing and Alzheimer's disease. Prog Neurobiol 2012;99:15-41
19. Cheung J, Rudolph MJ, Burhsteyn F, et al. Structures of human acetylcholinesterase in complex with pharmacologically important ligands. J Med Chem 2012;55:10282-6
20. Sugimoto H, Yamanishi Y, Iimura Y, et al. Donepezil hydrochloride (E2020) and other acetylcholinesterase inhibitors. Curr Med Chem 2000;7:303-39 (Pubitemid 30396441
21. Bartolini M, Bertucci C, Cavrini V, et al. beta-Amyloid aggregation induced by human acetylcholinesterase: Inhibition studies. Biochem Pharmacol 2003;65:407-16 (Pubitemid 36084557
22. Inestrosa N, Alvarez A, Perez C, et al. Acetylcholinesterase accelerates assembly of amyloid-beta-peptides into Alzheimer's fibrils: Possible role of the peripheral site of the enzyme. Neuron 1996;16:881-91 (Pubitemid 26124065
23. Inestrosa NC, Dinamarca MC, Alvarez A. Amyloid-cholinesterase interactions. FEBS J 2008;275:625-32
24. Rees T, Hammond PI, Soreq H, et al. Acetylcholinesterase promotes beta-Amyloid plaques in cerebral cortex. Neuorbiol Aging 2003;24:777-87 (Pubitemid 37288853
25. DeLano WL. The PyMOL molecular graphics system. DeLano Scientific; San Carlos, CA; 2012
26. Francis PT, Nordberg A, Arnold SE. A preclinical view of cholinesterase inhibitors in neuroprotection: Do they provide more than symptomatic benefits in Alzheimer's disease?. Trends Pharmacol Sci 2005;26:104-11
27. Akasofu S, Kosasa T, Kimura M, Kubota A. Protective effect of donepezil in a primary culture of rat cortical neurons exposed to oxygen-glucose deprivation. Eur J Pharmacol 2003;472(1-2):57-63 (Pubitemid 36830992
28. Shen H, Kihara T, Hongo H, et al. Neuroprotection by donepezil against glutamate excitotoxicity involves stimulation of a7 nicotinic receptors and internalization of NMDA receptors. Br J Phamracol 2010;161:127-39
29. Svensson AL, Nordberg A. Tacrine and donepezil attenuate the neurotoxic effect of A beta(25-35) in rat PC12 cells. Neuroreport 1998;9:1519-22
30. Sabbagh MN, Richardson S, Relkin N. Challenges and opportunities-Lessons from donepezil therapy. Alzheimers Dement 2008;4:109-18
31. Robertson IH. A noradrenergic theory of cognitive reserve: Implications for Alzheimer's disease. Neurobiol Aging 2013;34:298-308
32. Trillo L, Das D, Hsieh W, et al. Ascending monoaminergic systems alterations in Alzheimer's disease. Translating basic science into clinical care. Neuroscience 2013;37:1363-79
33. Čolović MB, Krstić DZ, Lazarević-Pašti TD, et al. Acetylcholinesterase inhibitors: Pharmacology and toxicology. Curr Neuropharmacol 2013;1:315-35
34. Aricept Product monography EISAI/Pfizer 1999
35. Tsuno N. Donepezil in the treatment of patients with Alzheimer's disease. Expert Rev Neurother 2009;9:591-8
36. ClinicalTrials.gov. A service of the U.S. National Institutes of Health. Washington, DC. Available from: Http://www.clinicaltrials.gov/ct2/results?. term=donepezil [Last accessed 12 November 2013
37. Müller T. Rivastigmine in the treatment of patients with Alzheimeŕs disease. Neuropsychiatr Dis Treat 2007;3(2):211-18
38. Polinsky RJ. Clinical pharmacology of rivastigmine: A new-generation acetylcholinesterase inhibitor for the treatment of Alzheimeŕs disease. Clin Ther 1998;20(4):634-47 (Pubitemid 28421485
39. Darreh-Shori T, Almkvist O, Guan ZZ, et al. Sustained cholinesterase inhibition in AD patients receiving rivastigmine for 12 months. Neurology 2002;59(4):563-72 (Pubitemid 34919991
40. Rokonczay Z. Potencies and selectivities of inhibitors of acetylcholinesterase and its molecular form in normal and Alzheimeŕs disease brain. Acta Biol Hung 2003;54(2):183-9
41. Darreh-Shori T, Vijayaraghavan S, Aeinehband S, et al. Functional variability in butyrylcholinesterase activity regulates intrathecal cytokine and astroglial biomarker profiles in patients with Alzheimeŕs disease. Neurobiol Aging 2013;34(11):2465-81
42. Onor ML, Trevisiol M, Aguglia E. Rivastigmine in the treatment of Alzheimeŕs disease: An update. Clin Interv Aging 2007;2(1):17-32
43. Guillzet AL, Smiley JF, Mash DC, Mesulam M. Butyrylcholinesterase in the life cycle of amyloid plaques. Ann Neurol 1997;42(6):909-18 (Pubitemid 28008422
44. Mesulam M, Geula C. Butyrylcholinesterase reactivity differentiates the amyloid plaques of aging from those of dementia. Ann Neurol 1994;36:722-7 (Pubitemid 24337630
45. Stefanova E, Blennow K, Almkvist O, et al. Cerebral glucose metabolism, cerebrospinal fluid-beta-Amyloid1-42/CSF-Abeta42), tau and apolipoprotein E genotype in long-Term rivastigmine and tacrine treated Alzheimeŕs disease (AD) patients. Neurosci Lett 2003;338:159-63 (Pubitemid 36140161
46. Bailey J, Ray B, Greig N, et al. Rivastigmine lowers Abeta and increases sAPPa levels, which parallel elevated synaptic markers and metabolic activity in degenerating primary rat neurons. PLoS One 2011;6(7):e21954
47. Birks J, Grimley EJ, Iakovidou V, et al. Rivastigmine for Alzheimer's disease. Cochrane Database Syst Rev 2009(2):CD001191
48. Cummings JL, Farlow MR, Meng X, et al. Rivastigmine transdermal patch skin tolerability: Results of a 1-year clinical trial in atients with mild-To-moderate Alzheimeŕs disease. Clin Drug Investig 2010;30(1):41-9
49. Farlow MR, Grossberg GT, Sadowsky CH, et al. A 24-week, randomized, controlled trial of rivastigmine patch 13.3 mg/24h versus 4.6mg/24h in severe Alzheimeŕs dementia. CNS Neurosci Ther 2013;19(10):745-52
50. Grossberg G, Cummings J, Frlich L, et al. Efficacy if higher dose 13.3 mg/24h rivastigmine patch on instrumentál activities of daily living in patients with mild-To-moderate Alzheimeŕs disease. Am J Alzheimers Dis Other Demen 2013;28:583-91
51. Priano L, Gasco ML, Mauro A. Transdermal treatment options for neurological disorders: Impact on the elderly. Drugs Aging 2006;23(5):357-75 (Pubitemid 44050424
52. Lefevre G, Sedek G, Jhee SS, et al. Pharmacokinetics and pharmacodynamics of the novel daily rivastigmine transdermal patch compared with twice-daily capsules in Alzheimer's disease patients. Clin Pharmacol Ther 2008;83(1):106-14
53. Winblad B, Grossberg G, Frohlich L, et al. IDEAL: A 6-month, doble-blind, placebo-controlled study of the first skin patch for Alzheimeŕs disease. Neurology 2007;69(4):S14-22
54. Grossberg GT, Stahelin HB, Messina JC, et al. Lack of adverse pharmacodynamics drug interactions with rivastigmine and twenty-Two classes of medications. Int J Geriatr Psychiatry 2000;15:242-7 (Pubitemid 30179175
55. Enz A, Gartsch C. Co-Administration of memantine has no effect on the in vitro or ex vivo determined acetylcholinesterase inhibition of rivastigmine in the rat brain. Neuropharmacology 2004;47(3):408-23
56. Barton DHR, Kirby GW. Phenol oxidation and biosynthesis. Part V. The synthesis of galanthamine. J Chem Soc 1962;806-17
57. Marco-Contelles J, do Carmo Carreiras M, Rodriguez C, et al. Synthesis and pharmacology of Galanthamine. Chem Rev 2006;106(1):116-33
58. Mashkovskii MD. Effects of galantamine on the acetylcholine sensitivity of skeletal musculature. Pharmacol Toxicol 1955;18:18-21
59. Jann MW, Shidey KL, Small GW. Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors. Clin Pharmacokinet 2002;41:719-39 (Pubitemid 34948194
60. Woodruff-Pak D, Lander C, Geerts H. Nicotinic cholinergic modulation: Galantamine as a prototype. CNS Drug Rev 2002;8:405-26 (Pubitemid 36114720
61. Huang F, Fu Y. A review of clinical pharmacocinetics and pharmacodynamics of galantamine, a reversible acetylcholinesterase inhibitor for the treatment of Alzheimeŕs disease, in healthy subject and patients. Curr Clin Pharmacol 2010;5:115-24
62. Greenblatt HM, Kryger G, Lewis T, et al. Structure of acetylcholinesterase complexed with (-)-galanthamine at 2.3A °resolution. FEBS Lett 1999;463:321-6 (Pubitemid 30001943
63. Samochodski M, H€offle A, Fehrenbacher A, et al. Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors. J Pharmacol Exp Ther 2003;305:1024-36 (Pubitemid 36617980
64. Maelicke A, Albuquerque EX. Allosteric modulation of nicotinic acetylcholine receptors as a treatment strategy for Alzheimeŕs disease. Eur J Pharmacol 2000;393:165-70 (Pubitemid 30193413
65. Ago Y, Koda K, Ota Y, et al. Donepezil, but not galanthamine, blocs muscarinic receptor-mediated in vitro and in vivo responses. Synapse 2011;65:1373-7
66. Coyle J, Kershaw P. Galanthamine, a cholinesterase inhibitor that allosterically modulates nicotinic receptors: Effects on the course of Alzheimeŕs disease. Biol Psychiatry 2001;49:289-99 (Pubitemid 32178438
67. Moriguchi S, Marszalec W, Zhao X, et al. Mechanism of action of galanthamine on N-methyl-D-Aspartate receptors in rat cortical neurons. J Pharmacol Exp Ther 2004;310:933-42 (Pubitemid 39108913
68. Takada-Takatori Y, Kume T, Izumi Y, et al. Roles of nicotinic receptors in acetylcholinesterase inhibitor-induces neuroprotection and nicotinic receptor up-regulation. Biol Pharm Bull 2009;32:318-24
69. Simoni E, Daniele S, Bottegoni G, et al. Combining galantamine and memantine in multitargeted, new chemical entities potentially useful in Alzheimer's disease. J Med Chem 2012;55:9708-21
70. Lopes JP, Tarozzo G, Reggiani A, et al. Galantamione potentiates the neuroprotectibe effect of memantine against NMDA-induces excitotoxicity. Brain Behav 2013;3:67-74
71. Matharu B, Gibson G, Parsons R, et al. Galantamine inhibits beta-Amyloid aggregation and cytotoxicity. J Neurol Sci 2009;280:49-58
72. Dineley KT, Westerman M, Bui D, et al. Beta-Amyloid activates the mitogenactivated protein kinase cascade via hippocampal alpha 7 nicotinic acetylcholine receptors: In vitro and in vivo mechanism related to Alzheimeŕs disease. J Neurol Sci 2001;21:4125-33 (Pubitemid 32538537
73. Melo JB, Sousa C, Garcao P, et al. Galanthamine prospects against oxidative stress induced by amyloid-beta peptide in cortical neurons. Eur J Neurosci 2009;29:455-64
74. Triana-Vidal LE, Carvajal-Varona SM. Protective effect of galantamine against oxidative damage using human lymphocytes: A novel in vitro model. Arch Med Res 2013;44:85-92
75. Hellstr€om-Lindahl E, Moore H, Nordberg A. Increased levels of tau protein in SH-SY5Y cells after treatment with cholinesterase inhibitors and nicotinic agonists. J Neurochem 2001;74:777-84 (Pubitemid 30053751
76. Raskind MA, Peskind ER, Wessel T, et al. Galanthamine in AD: A 6-month randomized, placebo-controlled trial with 6-month extension. The Galanthamine USA-1 Study Group. Neurology 2000;54:2261-8 (Pubitemid 30416276
77. Seltzer B. Galantamine-ER for th treatment of mild-To-moderate Alzheimeŕs disease. Clin Interv Aging 2010;5:1-6
78. Mannens GS, Snel CA, Hendrickx J, et al. The metabolism and excresion of galantamine in rats, dogs, and humans. Drug Metab Dispos 2002;30:553-63 (Pubitemid 34456978
79. Prvulovic D, Hampel H, Pantel J. Galantamine for Alzheimeŕs disease. Expert Opin Drug Metab Toxicol 2010;6:1-10
80. Shi J, Seltzer B. Galantamine: An update. Neurodegen Dis Manage 2011;1:227-34
81. Rutter AR, Freeman FM, Stephenson FA. Further characterization of the molecular interaction between PSD-95 and NMDA receptors: The effect of the NR1 splice variant and evidence for modulation of channel gating. J Neurochem 2002;81:1298-307 (Pubitemid 34809263
82. Olivares DK, Deshpande V, Shi YK, et al. Nmethyl d-Aspartate (NMDA) receptor antagonists and memantine treatment for Alzheimers disease, vascular dementia and Parkinsons disease. Curr Alzheimer Res 2012;9:746-58
83. Wolosker H, Radzishevsky I. The serine shuttle between glia and neurons: Implications for neurotransmission and neurodegeneration. Biochem Soc Trans 2013;41(6):1546-50
84. Reiser G, Binm€oller FJ, Koch R. Memantine (1-Amino-3,5- dimethyladamantane) blocks the serotonin-induced depolarization response in a neuronal cell line. Brain Res 1988;443(1-2):338-44 (Pubitemid 18062804
85. Rammes G, Rupprecht R, Ferrari U, et al. The N-methyl-D-Aspartate receptor channel blockers memantine, MRZ 2/579 and other amino-Alkyl- cyclohexanes antagonise 5-HT(3) receptor currents in cultured HEK-293 and N1E-115 cell systems in a non-competitive manner. Neurosci Lett 2001;306(1-2):81-4
86. Buisson B, Bertrand D. Open-channel blockers at the human alpha4beta2 neuronal nicotinic acetylcholine receptor. Mol Pharmacol 1998;53(3):555-63 (Pubitemid 28162880
87. Aracava Y, Pereira EF, Maelicke A, Albuquerque EX. Memantine blocks alpha7. * nicotinic acetylcholine receptors more potently than n-methyl-D-Aspartate receptors in rat hippocampal neurons. J pharmacol Exp Ther 2005;312(3):1195-205 (Pubitemid 40293781
88. Seeman P, Caruso C, Lasaga M. Memantine agonist action at dopamine D2High receptors. Synapse 2008;62(2):149-53
89. Brinkmann V, Billich A, Baumruker T, et al. Fingolimod (FTY720): Discovery and development of an oral drug to treat multiple sclerosis. Nat Rev Drug Discov 2010;9:883-97
90. Mills EJ, Thorlund K, Ioannidis JP. Demystifying trial networks and network meta-Analysis. BMJ 2013;346:f2914
91. Jansen JP, Fleurence R, Devine B, et al. Interpreting indirect treatment comparisons and network meta-Analysis for health-care decision making: Report of the ISPOR Task Force on indirect treatment comparisons good research practices-part 1. Value Health 2011;14:417-28
92. Hoaglin DC, Hawkins N, Jansen JP, et al. Interpreting indirect treatment comparisons and network meta-Analysis for health-care decision making: Report of the ISPOR Task Force on indirect treatment comparisons good research practices-part 2. Value Health 2011;14:429-37
93. Bond M, Rogers G, Peters J, et al The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): A systematic review and economic model. Health Technol Assess 2012;16(21):1-470
94. Cumbo E. Differential effects or rivastigmine, galantamine and donepezil on behavioral and psychological symptoms in patients with Alzheimer's disease: 18-month, randomized, open-label trial. Prim Care Community Psychiatr 2005;10:95-102 (Pubitemid 43355657
95. Fuschillo C, La Pia S, Campana F, et al. Cognitive deficits in Alzheimer's disease: Treatment with acetylcholinesterase inhibitor agents. Arch Gerontol Geriatr 2001;33:151-8 (Pubitemid 32727479
96. Wilkinson DG, Passmore AP, Bullock R, et al. A multinational, randomised, 12-week, comparative study of donepezil and rivastigmine in patients with mild to moderate Alzheimer's disease. Int J Clin Pract 2002;56:441-6 (Pubitemid 34855303
97. Jones RW, Soininen H, Hager K, et al. A multinational, randomised, 12-week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer's disease. Int J Geriatr Psychiatry 2004;19:58-67 (Pubitemid 38180693
98. Nordberg A, Darreh-Shori T, Peskind E, et al. Different cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients. Curr Alzheimer Res 2009;6:4-14
99. Ancoli-Israel S, Amatniek J, Ascher S, et al. Effects of galantamine versus donepezil on sleep in patients with mild to moderate Alzheimer disease and their caregivers: A double-blind, head-To-head, randomized pilot study. Alzheimer Dis Assoc Disord 2005;19:240-5 (Pubitemid 44366625
100. Available from: Http://www.consortstatement. org/ [Assessed on 20 Januray 2014
101. Bullock R, Touchon J, Bergman H, et al. Rivastigmine and donepezil treatment in moderate to moderately severe Alzheimer's disease over a 2-year period. Curr Med Res Opin 2005;21:1317-27 (Pubitemid 41140736
102. Drummond MF, Sculper MJ, Torrance GW, et al. Methods for the economic evaluation of health care programmes. 3rd edition. Oxford; University Press; 2005. ISBN 978-019-852945-3
103. Kobelt G. Health economics: An introduction to economic evaluation. 3rd edition. Office of Health Economics; 2013. ISBN 978-1-899040-44-5
104. McGregor M, Caro JJ. QALYs: Are they helpful to decision makers?. Pharmacoeconomics. Springer; 2006;24(10):947-52
105. Bar-on P, Millard CB, Harel M, et al. Kinetic and structural studies on the interaction of cholinesterases with the anti-Alzheimer drug rivastigmine. Biochemistry 2002;41:3555-64 (Pubitemid 34224667